1. HBW Insight
  2. >>Wellness
  3. >>Business

FDA Opens CBD Regulatory Path Docket, Warns Firms On Claims Missteps

 
• By Malcolm Spicer

With public hearing scheduled May 31 and a related public comment period, FDA "is interested in whether there are particular safety concerns that we should be aware of as we consider the FDA’s regulatory oversight and monitoring" of CBD products. Also influencing FDA's consideration is that CBD and other cannabis-derived substances are approved and being studied as drugs products, making their use as dietary ingredients noncompliant with agency regulations.

CBD Store

FDA wants public input on allowing cannabidiol's use in dietary supplements marketed with compliant claims, unlike the disease claims for CBD supplements made by three firms the agency recently warned.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

ProBiotix Health Looks To Next Level In Korea’s $450m Probiotics Market

 
• By Tom Gallen

Agreement with Seoul-based health and wellness player TopHealth will see the roll out of ProBiotix' cholesterol-lowering probiotics in South Korea.

Principle Relaunches Vitawell To Help Consumers Navigate UK Supplement ‘Minefield’

 
• By Tom Gallen

Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.

Evidence Doesn’t Scratch Substantiation Itch In NAD Review Of MagniLife Gel Pain Relief Claims

 
• By Malcolm Spicer

National Advertising Division finds Magni Group didn’t support claims made on MagniLife Gel packaging, in direct-mail advertisements and online and in social media “Rapid Pain Relief.”

SFI Expands Distribution Of Brain Health Supplement In Europe

 
• By Tom Gallen

Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.

More from Business